Trending Topic

Illustration of the thought processes in the brain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The prevalence of unruptured intracranial aneurysms (IAs) is approximately 3% of the population, with incidence on the rise due to the increased utilization of neuro-imaging for diverse objectives.1,2 The average risk of rupture for unruptured IA is estimated to vary from 0.3% to exceeding 15% per 5 years.3 Ruptured IA is the primary aetiology of […]

Renato Mantegazza, EAN 2021: Phase 3 ADAPT Study Results

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 5th 2021

touchNEUROLOGY met with Renato Mantegazza (Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan, Italy), to discuss the phase 3 ADAPT study results investigating efgartigimod for the treatment of myasthenia gravis.

The abstract entitled: ‘Safety and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis: Phase 3 ADAPT Study Results’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.

Questions:

  1. Could you tell us a little about efgartigimod and its mechanism of action? (0:19)
  2. Could you give us a brief overview of the ADAPT study objectives and its findings? (2:04)
  3. What are the potential side effects of efgartigimod? (3:50)
  4. What role is efgartigimod likely to play in the treatment paradigm of myasthenia gravis, and what further study is needed? (4:46)

Disclosures: Renato Mantegazza has received funding for Travel or Meeting attendance from, Alexion, Argenx, Biomarin Novartis, Catalyst, Merck Serono, UCB, and for Advisory Board participation from Alexion, Argenx, UCB, Regeneron.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch

Filmed as a highlight of the EAN Congress, Virtual 2021

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup